Russia Although Russian authorities received heavy criticism for approving the Sputnik V vaccine prior to the completion of Phase III clinical trials, the jab is increasingly being seen as a viable tool in the global fight against COVID-19. Sputnik V is now approved in a number of countries, but questions are…
Asia-Pacific UPS APAC’s Bee Lim describes how the logistics giant responded to the unprecedented challenges thrown up by the COVID-19 pandemic, the trends that the pandemic has accelerated in the region, and the talent profiles that UPS is looking for to ensure future success. The capabilities that we have built…
Dominican Republic Alejandro Paolini, Siemens Healthineers’ managing director for Mexico, Central America and Caribbean, dives into the medical technology industry’s business model transformation, switching from selling products to services with a risk-sharing approach. In addition, he reflects on the impact of the pandemic on the company’s performance, their unique presence in Central…
Turkey Turkey’s former Minister of Health, Bülent Akarcali, outlines the country’s healthcare system evolution over the past decades, comparing the improvements to the difference between a Ford Model T to a Tesla. In addition, he explains why medical tourism is and will continue to be a big business opportunity for Turkey…
LatAm Medtronic’s VP for North Latin America, Héctor Orellana, outlines the largest company’s new vision for that region, their efforts and challenges to continue gaining market access, and explains why the company is not shying away from Central America but rather doubling down. The region represents a great opportunity to…
Global The issue of COVID-19 vaccine access in developing nations has thrust intellectual property (IP) into global headlines. Against the backdrop of heated arguments both for and against an IP waiver for COVID-related products, the global pharma industry has launched a new initiative on IP, asserting its crucial importance to continued…
Singapore Cerecin’s Charles Stacey outlines the company’s progress in expanding its lead asset into migraine and infantile spasms, how its funding strategy has evolved, why Singapore is still a logical base, and how broader developments in the CNS landscape stand to benefit all stakeholders. Moving to Singapore was a good…
Pharma Legal Handbook Key facts about biosimilars and biologics in Mexico. Prepared in association with Olivares, a leading global law firm, this is an extract from The Pharma Legal Handbook: Mexico, available to purchase here for GBP 99. 1. Are biosimilar medicines considered the same as generic medicines in your country? No, biosimilars…
Pharma Legal Handbook Key facts about Localization in Mexico. Prepared in association with Olivares, a leading global law firm, this is an extract from The Pharma Legal Handbook: Mexico, available to purchase here for GBP 99. 1. Are there any rules or regulations requiring and/or encouraging localization in your country? What is the…
USA The day the Biden administration announced its support for the waiver of IP rights for COVID-19 vaccines, Moderna’s stock fell six percent; the day after that, another two percent. However, the Massachusetts-based company’s CEO Stephane Bancel remains unconcerned and believes that their successful vaccine is just the beginning of the mRNA era…
Pharma Legal Handbook Important legal info for orphan drugs and rare diseases in Mexican pharma. Prepared in association with Olivares, a leading global law firm, this is an extract from The Pharma Legal Handbook: Mexico, available to purchase here for GBP 99. 1. What is the definition of Rare Diseases in your…
Japan The latest from Japanese pharma, including Takeda’s big profit jump, British Linepharma’s quest to get the first ever induced abortion pill for practical use, Shionogi’s promise to become the first Japanese company to get a COVID-19 vaccine approved, and the Japanese industry’s opposition to the Biden administration’s support for a…
See our Cookie Privacy Policy Here